1Q22 Added 19,673 New SubscribersRevenues Up 12.2% YoY to RMB315.2 Million ($48.8 Million)Gross Profit Up 12.6% YoY to RMB267.3 Million ($41.4 Million)OperatingIncome Up 17.3% YoY to RMB156.6 Million ($24.2 Million)Non-GAAP Operating Income Up 15.5% YoY to RMB168.5 Million ($26.1 Million)Conference Call to be Held on August 31, 2021, at 8:00 a.m. ET
HONG KONG, Aug. 30, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2022, ended June 30, 2021.
First Quarter of Fiscal 2022 Highlights
"We recorded 19,673 new subscribers during the first quarter of fiscal 2022, as China's approach largely kept COVID-19 under control and consumer concerns gradually alleviated." said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "However, despite current policy stimulus on newborn, we remain cautious about our near-term outlook due to factors that include the recent reimplementation of COVID-related lockdowns, general regulatory uncertainty, potential changes to the market dynamics affecting China's cord blood banking industry and the downward newborn trend in our operating markets. With a focus on enhancing our risk-resistance capacities, we continue to prepare for potential structural and regulatory changes to ensure the long-term growth of the Company."
Summary First Quarter Ended June 30, 2020 and 2021
Three Months Ended June 30,
2020
2021
(in thousands)
RMB
RMB
US$
Revenues
280,913
315,174
48,814
Gross Profit
237,450
267,333
41,405
Operating Income[3]
133,509
156,556
24,249
Change in Fair Value of Equity Securities
18,405
5,601
867
Dividend Income
-
1,120
173
Net Income Attributable to the Company'sShareholders
132,509
136,421
21,130
Earnings per Ordinary Share(RMB/US$) Basic
1.09
1.12
0.17
Diluted
1.09
1.12
0.17
Revenue Breakdown (%)
Processing Fees and Other Services
57.5%
58.6%
Storage Fees
42.5%
41.4%
New Subscribers (persons)
17,233
19,673
Total Accumulated Subscribers(persons)
849,933
920,195[1]
Summary Selected Cash Flow Statement Items
Three Months Ended June 30,
2020
2021
(in thousands)
RMB
RMB
US$
Net cash provided by operating activities
99,829
172,823
26,767
Net cash used in investing activities
(7,444)
(2,546)
(394)
Net cash used in financing activities
-
(7,729)
(1,197)
First Quarter of Fiscal 2022 Financial Results
REVENUES. Revenues increased by 12.2% YoY to RMB315.2 million ($48.8 million) in the first quarter of fiscal 2022. The increase was mainly attributable to the increase in processing fee revenues due to the increase in new subscribers as well as increase in storage fee revenues as a result of an enlarged subscriber base.
During the first quarter our new subscriber numbers for the reporting period increased by 14.2% YoY to 19,673, due in part to China's effective control of 2019 novel coronavirus ("COVID-19") gradually alleviating consumer concerns over childbirth and spending; combined with a relatively low base in the first quarter of last fiscal year early in the COVID-19 pandemic. Revenues generated from processing fees and other services in the reporting quarter increased accordingly by 14.3% YoY to RMB184.7 million ($28.6 million).
By the end of June 2021, the Company's accumulated subscriber base expanded to 920,195[1], as revenues generated from storage fees increased by 9.4% YoY to RMB130.5 million ($20.2 million) in the reporting quarter. Storage fee revenues represented 41.4% of total revenues, down from 42.5% in the prior year period.
GROSS PROFIT. Gross profit for the reporting quarter increased by 12.6% YoY to RMB267.3 million ($41.4 million), in line with topline growth. Gross margin improved slightly to 84.8% from 84.5% in the prior year period.
OPERATING INCOME. With slower increase in sales and marketing and general and administrative expenses, operating income for the reporting quarter increased by 17.3% YoY to RMB156.6 million ($24.2 million). Operating margin expanded to 49.7% in the reporting quarter from 47.5% in the prior year period. Depreciation and amortization expenses for the first quarter amounted RMB11.9 million ($1.8 million). Non-GAAP operating income[2] improved by 15.5% YoY to RMB168.5 million ($26.1 million).
Research and Development Expenses. Research and development expenses for the first quarter increased by 17.3% YoY to RMB5.1 million ($0.8 million), in line with management expectations.
Sales and Marketing Expenses. As the Company cautiously rode the tide of consumer sentiment recovery, sales and marketing expenses for the reporting quarter increased by 7.9% YoY to RMB59.4 million ($9.2 million) due to higher sales performance incentives, partially offset by controlled marketing spending. Sales and marketing expenses as a percentage of revenues decreased to 18.8% from 19.6% in the prior year period.
General and Administrative Expenses. General and administrative expenses for the first quarter increased by 3.9% YoY to RMB46.3 million ($7.2 million), mainly driven by increases in provisions and professional fees, partially offset by lower overhead. General and administrative expenses as a percentage of revenues decreased to 14.7% from 15.9% in the prior year period.
OTHER INCOME AND EXPENSES.
Change in Fair Value of Equity Securities. In the first quarter, the Company recognized an increase in fair value of equity securities, or "mark-to-market gains," of RMB5.6 million ($0.9 million), compared to RMB18.4 million in the prior year period. The changes were mainly attributable to the valuation of the Company's investments in equity securities.
Dividend Income. In the reporting quarter, the Company received RMB1.1 million ($0.2 million) dividend income from the Company's equity investments, whereas no such income was recorded in the prior year period.
NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. As a result of the increases in operating income and dividend income, partially compensated by the decrease in mark-to-market gains, income before income tax for the first quarter increased by 7.4% YoY to RMB172.3 million ($26.7 million). Income tax expense for the reporting quarter was RMB33.3 million ($5.2 million). Net income attributable to the Company's shareholders for the reporting quarter increased by 3.0% YoY to RMB136.4 million ($21.1 million). Net margin for the first quarter was 43.3%.
EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the first quarter fiscal 2022 increased by 2.8% YoY to RMB1.12 ($0.17).
Corporate Developments
Conference Call
The Company will host a conference call at 8:00 a.m. ET on Tuesday, August 31, 2021 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-855-824-5644 or 1-646-722-4977 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 54240817#.
[1]During the three months ended June 30, 2021, 19,673 new subscribers were recruited. During the three months ended June 30, 2021, the Company determined that the recoverability of 915 private cord blood units was remote and therefore, the Company terminated their subscription services according to the subscription contracts. Out of these prior private cord blood units, 715 prior private cord blood units were being treated as if they were donated cord blood units and will be part of the Company's non-current inventories. Hence, the net accumulated subscriber base was 920,195 as of June 30, 2021.
[2]See exhibit 3 to this press release for a reconciliation of non-GAAP operating income to exclude the non-cash items related to the depreciation and amortization expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").
[3]The reported operating income for the three months ended June 30, 2020 and 2021 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB12.4 million and RMB11.9 million ($1.8 million), respectively.
Use of Non-GAAP Financial Measures
GAAP results for the three months ended June 30, 2021 include non-cash items related to depreciation and amortization expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.
About Global Cord Blood Corporation
Read this article:
- Stem Cell Banking Market Size To Surpass USD 19.29 Billion By 2030, Exhibiting A CAGR Of 13.69% As Revealed... - WhaTech - March 18th, 2024
- Stem Cell Banking Market Size, Share, Competitive Landscape and Trend Analysis and Industry Forecast, - EIN News - January 18th, 2024
- Stem Cell Banking Market Predicted to Witness Steady Growth ... - Digital Journal - September 8th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR 15.6% - EIN News - September 7th, 2023
- Stem Cell Banking Market Trends: Industry Analysis and Growth Projections Through 2030 - Benzinga - September 3rd, 2023
- Stem Cell Banking Market Report: Analysis of Effective Business ... - Digital Journal - August 30th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR of 15.6% - openPR - July 19th, 2023
- Stem Cell Banking Market expected to reach USD 16,474.30 million by 2029 - openPR - July 8th, 2023
- Global Stem Cell Banking Market is expected to reach a market size of ~US$ 15 billion by 2028: Ken Research - openPR - June 8th, 2023
- Stem Cell Banking Market: CAGR of 8.2% and Market Valuation ... - KaleidoScot - June 8th, 2023
- Cord Stem Cell Banking Market Size to Surpass USD 45.64 Billion with CAGR of 22% by 2030 - openPR - June 4th, 2023
- Forecasting the Future of the Stem Cell Banking Market : Trends and Insights | CCBC, Crioestaminal, Esperite, - openPR - April 29th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | Current Trends and Industry Analysis - EIN News - April 27th, 2023
- Stem Cell Banking Offers Health And Investment Opportunity - ValueWalk - April 21st, 2023
- Stem Cell Banking Offers Health and Investment Opportunity ... - SavingAdvice.com - April 19th, 2023
- Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 - openPR - April 12th, 2023
- Stem Cell Banking Market Size Expected to Reach USD 16,474.30 Million by 2029 with 16.1% CAGR - openPR - March 29th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- Stem Cell Banking Market Top-Players And Qualitative Future ... - Digital Journal - February 13th, 2023
- Global Stem Cell Banking Market Overview, Regional Analysis, Market Share and Competitive Analysis - openPR - February 4th, 2023
- What is Stem Cell Banking? | Stem Cell Preservation in India | Stem ... - January 7th, 2023
- Stem Cell & Cord Blood Banking Dubai, UAE - CellSave Arabia - January 5th, 2023
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - January 5th, 2023
- Private stem cell banking & genetic screening | Future Health Biobank - December 24th, 2022
- Stem Cell Banking Outsourcing Market is anticipated to expand at a ... - Digital Journal - December 20th, 2022
- Stem Cell Banking market size is estimated to be worth USD 1789 million in 2021 and is forecast to a readjuste - openPR - December 15th, 2022
- Stem Cell Banking Market To Reach USD 2927.2 Million By 2028 With A CAGR of 7.2% | Valuates Reports - Yahoo Finance - December 11th, 2022
- Stem Cell Banking Market registering a CAGR of 16.1% by forecast 2029 - openPR - December 1st, 2022
- Stem Cell Banking Industry 2022 - 2028 Market Analysis by Regions, Types and Application - openPR - November 6th, 2022
- Stem Cell Banking & Therapy In India | ReeLabs - October 25th, 2022
- Worldwide Stem Cell Banking Industry to 2027 - Rising Number of Fatal ... - October 25th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 25th, 2022
- Placental Stem Cell Therapy Market - Know the Latest Profit Sources of the Industry - openPR - October 18th, 2022
- Outlook on the Cord Blood Banking Services Global Market to 2027 - by Component, Storage Services, Application and Region - GlobeNewswire - October 13th, 2022
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR - October 12th, 2022
- News from the world of Education: October 12, 2022 - The Hindu - October 12th, 2022
- Stemcord | Home - October 9th, 2022
- Global Cord Blood Banking Market - Competition Forecast and Opportunities, 2027 - Yahoo Finance - October 9th, 2022
- Cell Banking Outsourcing Market Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2031 The Colby Echo News - The Colby Echo... - October 4th, 2022
- Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands - Business Wire - September 29th, 2022
- Biobanking Market Size to Surge at the CAGR of 5.9% from 2022-2031 - Digital Journal - September 19th, 2022
- Stem Cell Banking Solutions | Hope Biosciences - September 19th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 17th, 2022
- Stem Cell Banking Market to Witness Massive Growth by 2029 | CCBC, CBR - Fighting Hawks Magazine - Fighting Hawks Magazine - September 15th, 2022
- Stem Cell Banking Market Analysis, 2031: Advancements in the field of Regenerative Medicine - BioSpace - September 15th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 15th, 2022
- Cord Blood Banking Services Market Size Estimated to Reach $3.6 Billion By 2027 at a CAGR of 11.8% During Forecast Period 2022-2027. - Digital Journal - August 30th, 2022
- Applied StemCell expands manufacturing facility to support cell and gene therapies - BioPharma-Reporter.com - August 30th, 2022
- What is Cord Blood Banking? - Benzinga - August 30th, 2022
- Vita 34 records moderate upward trend in the second quarter - PharmiWeb.com - August 30th, 2022
- dental stem cell banking - National Dental Pulp Laboratory - August 29th, 2022
- Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell... - August 24th, 2022
- Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells - Nature.com - August 12th, 2022
- Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu - August 10th, 2022
- Building a healthtech industry in Europe to serve patients - Labiotech.eu - August 9th, 2022
- Cell & Gene Therapy Manufacturing Services Market Research Report : With Healthy CAGR 7.8% : Will Reach USD 56.7 Billion by 2028 - Digital Journal - August 6th, 2022
- Oldest patient yet cured of HIV after stem cell transplant researchers - Global Banking And Finance Review - July 28th, 2022
- Stem Cell Banking Market Size to Accelerate at a Rapid CAGR of 16.1% from 2022 to 2029 - Digital Journal - July 25th, 2022
- Global Stem Cell Banking Outsourcing Market 2022 Trend Analysis, Growth Status, Revenue Expectation to 2028 This Is Ardee - This Is Ardee - July 19th, 2022
- Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million - Business Wire - July 14th, 2022
- Stem Cell Banking Market Detailed In New Research Report 2022 | Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH... - July 12th, 2022
- Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM - Yahoo Finance - July 7th, 2022
- Cord Stem Cell Banking Market Size, Global Industry, Share, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by DBMR... - July 7th, 2022
- Allogenic Stem Cell Therapy Market Research by Size, Share, Trends, Business Opportunities and Top Manufacture and Forecast by 2027 Designer Women -... - July 7th, 2022
- expert reaction to study that uses freeze-dried somatic cells to produce cloned mice - Science Media Centre - July 5th, 2022
- South Korea Stem Cell Banking Market Report 2022 - ResearchAndMarkets.com - Business Wire - July 4th, 2022
- Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., ... - The Bakersfield Californian - June 30th, 2022
- NorthX jumps into cell therapies with help from Alder - Bioprocess Insider - BioProcess Insider - June 28th, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - PharmiWeb.com - June 26th, 2022
- Cord Stem Cell Banking Market Size, Share, Application, Trends, Growth, Opportunities and Worldwide Forecast Designer Women - Designer Women - June 24th, 2022
- Indian Optical Brightening Agents Market To Be Driven By Rising Manufacturing Operations In The Forecast Period Of 2022-2027 Designer Women -... - June 22nd, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - Yahoo Finance UK - June 22nd, 2022
- Stem Cell Banking Market Global Outlook on Key Growth Trends, Factors and Forecast 2028: Cord Blood Registry (CBR) Systems, Inc.,Cryo-Cell... - June 22nd, 2022
- Pricing & Payment Plans | AlphaCord - Newborn Stem Cell Banking - June 20th, 2022
- Global Cholera Vaccine Market Garnered a Revenue of Approximately USD 68 Million in 2021 and Further Touch a CAGR of ~7% During 2022-2030; Market to... - June 20th, 2022
- Global Potash Fertilisers Market To Be Driven By Changing Food Habits Among Customers In The Forecast Period Of 2022-2027 Designer Women - Designer... - June 18th, 2022
- Stem Cell Banking Outsourcing Market 2022 with a CAGR of %, prime firms report covers, business Outlook, In-depth Analysis Business Opportunities and... - June 18th, 2022
- Global Stem Cell Banking Market To Be Driven At A CAGR Of 13.5% In The Forecast Period Of 2021-2026 Designer Women - Designer Women - June 15th, 2022
- The age reversal tech that billionaires are banking on - Freethink - June 15th, 2022
Recent Comments